Trade Q32 Bio Inc - QTTB CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.0205 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Homology Medicines Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 0.8981 |
| Open* | 0.8971 |
| 1-Year Change* | -0.23% |
| Day's Range* | 0.8971 - 0.9671 |
| 52 wk Range | 0.46-1.76 |
| Average Volume (10 days) | 209.20K |
| Average Volume (3 months) | 7.05M |
| Market Cap | 33.46M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 57.93M |
| Revenue | 1.96M |
| EPS | -2.27 |
| Dividend (Yield %) | N/A |
| Beta | -0.16 |
| Next Earnings Date | Mar 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 25, 2024 | 0.9171 | 0.0199 | 2.22% | 0.8972 | 0.9695 | 0.8971 |
| Mar 22, 2024 | 0.8981 | 0.0294 | 3.38% | 0.8687 | 0.9321 | 0.8537 |
| Mar 21, 2024 | 0.8819 | 0.0138 | 1.59% | 0.8681 | 0.8922 | 0.8671 |
| Mar 20, 2024 | 0.8931 | 0.0145 | 1.65% | 0.8786 | 0.9170 | 0.8571 |
| Mar 19, 2024 | 0.8973 | -0.0098 | -1.08% | 0.9071 | 0.9322 | 0.8783 |
| Mar 18, 2024 | 0.8973 | 0.0002 | 0.02% | 0.8971 | 0.9021 | 0.8651 |
| Mar 15, 2024 | 0.9171 | 0.0000 | 0.00% | 0.9171 | 0.9251 | 0.9071 |
| Mar 14, 2024 | 0.9171 | 0.0100 | 1.10% | 0.9071 | 0.9501 | 0.9071 |
| Mar 13, 2024 | 0.9071 | 0.0300 | 3.42% | 0.8771 | 0.9071 | 0.8771 |
| Mar 12, 2024 | 0.8946 | 0.0175 | 2.00% | 0.8771 | 0.8971 | 0.8771 |
| Mar 11, 2024 | 0.9069 | 0.0298 | 3.40% | 0.8771 | 0.9069 | 0.8771 |
| Mar 8, 2024 | 0.8869 | -0.0003 | -0.03% | 0.8872 | 0.8981 | 0.8771 |
| Mar 7, 2024 | 0.8995 | -0.0070 | -0.77% | 0.9065 | 0.9071 | 0.8471 |
| Mar 6, 2024 | 0.8971 | 0.0300 | 3.46% | 0.8671 | 0.8971 | 0.8671 |
| Mar 5, 2024 | 0.8669 | -0.0102 | -1.16% | 0.8771 | 0.8874 | 0.8585 |
| Mar 4, 2024 | 0.8917 | -0.0083 | -0.92% | 0.9000 | 0.9000 | 0.8640 |
| Mar 1, 2024 | 0.8931 | -0.0369 | -3.97% | 0.9300 | 0.9400 | 0.8800 |
| Feb 29, 2024 | 0.9200 | 0.0189 | 2.10% | 0.9011 | 0.9300 | 0.8828 |
| Feb 28, 2024 | 0.9200 | 0.0013 | 0.14% | 0.9187 | 0.9348 | 0.8960 |
| Feb 27, 2024 | 0.9150 | 0.0230 | 2.58% | 0.8920 | 0.9194 | 0.8700 |
Q32 Bio Inc Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 3.208 | 33.971 | 2.702 | 1.666 | 5.322 |
| Revenue | 3.208 | 33.971 | 2.702 | 1.666 | 5.322 |
| Total Operating Expense | 5.24 | 129.92 | 132.965 | 111.609 | 65.248 |
| Selling/General/Admin. Expenses, Total | 38.138 | 36.835 | 32.573 | 22.211 | 17.3 |
| Research & Development | 98.351 | 93.085 | 100.392 | 89.398 | 47.948 |
| Operating Income | -2.032 | -95.949 | -130.263 | -109.943 | -59.926 |
| Interest Income (Expense), Net Non-Operating | 3.23 | 0.185 | 1.569 | 6.027 | 4.349 |
| Other, Net | |||||
| Net Income Before Taxes | 1.198 | -95.764 | -128.694 | -103.916 | -55.577 |
| Net Income After Taxes | 0.483 | -95.764 | -128.694 | -103.916 | -55.577 |
| Net Income Before Extra. Items | -5.005 | -95.764 | -128.694 | -103.916 | -55.577 |
| Net Income | -5.005 | -95.764 | -128.694 | -103.916 | -55.577 |
| Income Available to Common Excl. Extra. Items | -5.005 | -95.764 | -128.694 | -103.916 | -55.577 |
| Income Available to Common Incl. Extra. Items | -5.005 | -95.764 | -128.694 | -103.916 | -55.577 |
| Diluted Net Income | -5.005 | -95.764 | -128.694 | -103.916 | -55.577 |
| Diluted Weighted Average Shares | 57.3998 | 55.2833 | 45.9108 | 42.1177 | 28.5518 |
| Diluted EPS Excluding Extraordinary Items | -0.0872 | -1.73224 | -2.80313 | -2.46728 | -1.94653 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -1.57347 | -1.73224 | -2.80313 | -2.46728 | -1.94653 |
| Unusual Expense (Income) | -131.249 | ||||
| Equity In Affiliates | -5.488 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.354 | 0.802 | 0.802 | 0.802 | 0.802 |
| Revenue | 0.354 | 0.802 | 0.802 | 0.802 | 0.802 |
| Total Operating Expense | 31.17 | 28.313 | 35.296 | 33.664 | 29.109 |
| Selling/General/Admin. Expenses, Total | 8.188 | 8.325 | 8.147 | 7.81 | 8.034 |
| Research & Development | 22.982 | 19.988 | 27.149 | 25.854 | 21.075 |
| Operating Income | -30.816 | -27.511 | -34.494 | -32.862 | -28.307 |
| Interest Income (Expense), Net Non-Operating | 1.511 | 1.469 | 1.455 | 1.269 | 0.474 |
| Net Income Before Taxes | -29.305 | -26.042 | -33.039 | -31.593 | -27.833 |
| Net Income After Taxes | -29.305 | -26.042 | -32.938 | -31.547 | -27.728 |
| Net Income Before Extra. Items | -35.044 | -28.844 | -34.295 | -33.726 | -29.089 |
| Net Income | -35.044 | -28.844 | -34.295 | -33.726 | -29.089 |
| Income Available to Common Excl. Extra. Items | -35.044 | -28.844 | -34.295 | -33.726 | -29.089 |
| Income Available to Common Incl. Extra. Items | -35.044 | -28.844 | -34.295 | -33.726 | -29.089 |
| Diluted Net Income | -35.044 | -28.844 | -34.295 | -33.726 | -29.089 |
| Diluted Weighted Average Shares | 57.7953 | 57.7163 | 57.4818 | 57.4472 | 57.3856 |
| Diluted EPS Excluding Extraordinary Items | -0.60635 | -0.49975 | -0.59662 | -0.58708 | -0.5069 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.60635 | -0.49975 | -0.59662 | -0.58708 | -0.5069 |
| Unusual Expense (Income) | 0 | 0 | 0 | 0 | 0 |
| Equity In Affiliates | -5.739 | -2.802 | -1.357 | -2.179 | -1.361 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 181.015 | 191.909 | 219.564 | 266.577 | 221.685 |
| Cash and Short Term Investments | 175.026 | 155.873 | 217.431 | 262.388 | 214.737 |
| Cash | 0.019 | 0.059 | 0.25 | 0.25 | 0.471 |
| Cash & Equivalents | 33.967 | 108.323 | 217.181 | 39.524 | 31.74 |
| Short Term Investments | 141.04 | 47.491 | 0 | 222.614 | 182.526 |
| Prepaid Expenses | 5.989 | 7.129 | 2.133 | 4.189 | 6.948 |
| Other Current Assets, Total | 28.907 | ||||
| Total Assets | 228.47 | 211.721 | 263.737 | 310.567 | 259.094 |
| Property/Plant/Equipment, Total - Net | 21.641 | 17.859 | 42.899 | 42.716 | 35.637 |
| Property/Plant/Equipment, Total - Gross | 27.877 | 23.705 | 59.274 | 51.126 | 37.745 |
| Accumulated Depreciation, Total | -6.236 | -5.846 | -16.375 | -8.41 | -2.108 |
| Other Long Term Assets, Total | 0 | 1.953 | 1.274 | 1.274 | 1.772 |
| Total Current Liabilities | 22.576 | 17.226 | 22.658 | 12.374 | 22.519 |
| Accounts Payable | 1.144 | 2.366 | 4.722 | 2.608 | 15.732 |
| Accrued Expenses | 20.276 | 11.652 | 12.304 | 7.644 | 5.04 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.156 | 3.208 | 5.632 | 2.122 | 1.747 |
| Total Liabilities | 50.492 | 42.07 | 67.742 | 52.06 | 62.739 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 27.916 | 24.844 | 45.084 | 39.686 | 40.22 |
| Total Equity | 177.978 | 169.651 | 195.995 | 258.507 | 196.355 |
| Preferred Stock - Non Redeemable, Net | |||||
| Common Stock | 0.006 | 0.006 | 0.005 | 0.004 | 0.003 |
| Additional Paid-In Capital | 607.513 | 593.784 | 524.358 | 457.994 | 292.187 |
| Retained Earnings (Accumulated Deficit) | -429.137 | -424.132 | -328.368 | -199.674 | -95.758 |
| Unrealized Gain (Loss) | -0.404 | -0.007 | 0.183 | -0.077 | |
| Total Liabilities & Shareholders’ Equity | 228.47 | 211.721 | 263.737 | 310.567 | 259.094 |
| Total Common Shares Outstanding | 57.4839 | 57.1503 | 50.2656 | 45.1167 | 37.3585 |
| Long Term Investments | 25.814 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 106.635 | 131.336 | 153.583 | 181.015 | 213.204 |
| Cash and Short Term Investments | 103.298 | 127.071 | 150.025 | 175.026 | 201.074 |
| Cash & Equivalents | 29.111 | 76.797 | 39.454 | 33.986 | 43.162 |
| Short Term Investments | 74.187 | 50.274 | 110.571 | 141.04 | 157.912 |
| Prepaid Expenses | 3.023 | 4.265 | 3.558 | 5.989 | 12.13 |
| Total Assets | 140.063 | 169.337 | 197.881 | 228.47 | 262.651 |
| Property/Plant/Equipment, Total - Net | 19.471 | 20.682 | 21.262 | 21.641 | 22.315 |
| Property/Plant/Equipment, Total - Gross | 19.471 | 27.275 | 27.638 | 27.877 | 29.158 |
| Accumulated Depreciation, Total | 0 | -6.593 | -6.376 | -6.236 | -6.843 |
| Other Long Term Assets, Total | 0 | 0 | |||
| Total Current Liabilities | 25.292 | 22.939 | 18.507 | 22.576 | 25.252 |
| Accounts Payable | 7.803 | 3.393 | 3.635 | 1.144 | 4.835 |
| Accrued Expenses | 17.489 | 19.546 | 14.518 | 20.276 | 18.459 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 0 | 0.354 | 1.156 | 1.958 |
| Total Liabilities | 51.852 | 49.962 | 45.982 | 50.492 | 53.59 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 26.56 | 27.023 | 27.475 | 27.916 | 28.338 |
| Total Equity | 88.211 | 119.375 | 151.899 | 177.978 | 209.061 |
| Common Stock | 0.006 | 0.006 | 0.006 | 0.006 | 0.006 |
| Additional Paid-In Capital | 614.22 | 612.482 | 610.056 | 607.513 | 604.354 |
| Retained Earnings (Accumulated Deficit) | -525.979 | -493.025 | -457.981 | -429.137 | -394.842 |
| Unrealized Gain (Loss) | -0.036 | -0.088 | -0.182 | -0.404 | -0.457 |
| Total Liabilities & Shareholders’ Equity | 140.063 | 169.337 | 197.881 | 228.47 | 262.651 |
| Total Common Shares Outstanding | 57.9022 | 57.7981 | 57.7948 | 57.4839 | 57.4806 |
| Other Current Assets, Total | 0.314 | 0 | |||
| Long Term Investments | 13.957 | 17.319 | 23.036 | 25.814 | 27.132 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -5.005 | -95.764 | -128.694 | -103.916 | -57.215 |
| Cash From Operating Activities | -113.661 | -109.751 | -94.332 | -91.358 | -42.562 |
| Cash From Operating Activities | 1.293 | 8.353 | 7.965 | 6.318 | 1.289 |
| Non-Cash Items | -113.299 | 19.463 | 14.877 | 5.777 | 1.161 |
| Changes in Working Capital | 3.35 | -41.803 | 11.52 | 0.463 | 12.203 |
| Cash From Investing Activities | 36.716 | -50.788 | 204.896 | -51.799 | -121.787 |
| Capital Expenditures | -1.285 | -2.396 | -3.733 | -21.833 | -24.939 |
| Other Investing Cash Flow Items, Total | 38.001 | -48.392 | 208.629 | -29.966 | -96.848 |
| Cash From Financing Activities | 0.596 | 52.169 | 53.093 | 158.213 | 150.994 |
| Issuance (Retirement) of Stock, Net | 0.596 | 52.169 | 53.093 | 158.213 | 150.994 |
| Net Change in Cash | -76.349 | -108.37 | 163.657 | 15.056 | -13.355 |
| Cash Taxes Paid | 0.72 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -28.844 | -5.005 | 29.29 | 63.016 | 92.105 |
| Cash From Operating Activities | -26.054 | -113.661 | -86.462 | -61.53 | -30.684 |
| Cash From Operating Activities | 0.225 | 1.293 | 0.997 | 0.676 | 0.348 |
| Non-Cash Items | 4.635 | -113.299 | -117.056 | -121.539 | -126.372 |
| Changes in Working Capital | -2.07 | 3.35 | 0.307 | -3.683 | 3.235 |
| Cash From Investing Activities | 31.372 | 36.716 | 18.725 | 126.943 | 168.312 |
| Capital Expenditures | -0.228 | -1.285 | -1.276 | -1.27 | -1.149 |
| Other Investing Cash Flow Items, Total | 31.6 | 38.001 | 20.001 | 128.213 | 169.461 |
| Cash From Financing Activities | 0.15 | 0.596 | 0.564 | 0.44 | 0.44 |
| Issuance (Retirement) of Stock, Net | 0.15 | 0.596 | 0.564 | 0.44 | 0.44 |
| Net Change in Cash | 5.468 | -76.349 | -67.173 | 65.853 | 138.068 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Homology Medicines Company profile
About Homology Medicines Inc
Homology Medicines, Inc. is a clinical-stage genetic medicines company. The Company focuses on patients suffering from rare genetic diseases by curing the underlying cause of the disease. Its platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs), to deliver single administration genetic medicines in vivo either through gene therapy or nuclease-free gene editing across a range of genetic disorders. Its various set of AAVHSCs allows it to target, via a single injection, a range of disease-relevant tissues, including the liver, central nervous system (CNS), peripheral nervous system (PNS), bone marrow, muscle and eye. Its lead product candidate, HMI-102, is a gene therapy for the treatment of adults with phenylketonuria (PKU). Its other gene therapy product development candidates for the treatment of lysosomal storage diseases are HMI-203, for the treatment of mucopolysaccharidosis type II (MPS II) and HMI-202.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Homology Medicines Inc revenues increased from $1.7M to $33.2M. Net loss decreased 37% to $62.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 13% to $63.1M (expense), General and administrative - Balancing decrease of 1% to $19.8M (expense).
| Industry: | Bio Therapeutic Drugs |
1 Patriots Park
BEDFORD
MASSACHUSETTS 01730-2343
US
Income Statement
- Annual
- Quarterly
News
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024
Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com